Feng-min Lu

Feng-min Lu


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2006 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MGMingzhou Guo
Mingzhou Guo
SLShuang Liu
Shuang Liu
FLFeng-min Lu
Feng-min Lu
The sensitivity of lung cancer to gefitinib has been found to be associated with mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR),1-3 yet similar observations are not available for other solid tumors.4 We investigated whether gefitinib-sensitizing mutations in the EGFR gene were present in human esophageal tumors.

1 January 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
TLTianhui Liu
Tianhui Liu
MYMingjie Yao
Mingjie Yao
SLShuhong Liu
Shuhong Liu
LWLu Wang
Lu Wang
LWLeijie Wang
Leijie Wang
FLFeng-min Lu
Feng-min Lu
Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma

1 January 2015 in World Journal of Gastroenterology
Verified
Journal Article
Open access
SDShan-Long Ding
Shan-Long Ding
ZYZi-Wei Yang
Zi-Wei Yang
JWJie Wang
Jie Wang
XZXiao-Lei Zhang
Xiao-Lei Zhang
XCXiang-Mei Chen
Xiang-Mei Chen
FLFeng-min Lu
Feng-min Lu
AIM: To comprehensively understand the underlying molecular events accounting for aberrant Wnt signaling activation in hepatocellular carcinoma (HCC). METHODS: This study was retrospective. The HCC tissue specimens used in this research were obtained from patients who underwent liver surgery. The Catalogue of Somatic Mutations in Cancer (COSMIC) database was searched for the mutation statuses of CTNNB1, TP53, and protein degradation regulator genes of CTNNB1. Dual-luciferase reporter assay was performed with TOP/FOP reporters to detect whether TP53 gain-of-function (GOF) mutations could enhance the transcriptional activity of Wnt signaling. Methylation sensitive restriction enzyme-quantitative PCR was used to explore the methylation status of CpG islands located in the promoters of APC, SFRP1, and SFRP5 in HCCs with different risk factors. Finally, nested-reverse transcription PCR was performed to examine the integration of HBx in front of LINE1 element and the existence of HBx-LINE1 chimeric transcript in Hepatitis B virus-related HCC. All results in this article were analyzed with the software SPSS version 19.0 for Windows, and different groups were compared by χ2 test as appropriate. RESULTS: Based on the data from COSMIC database, compared with other solid tumors, mutation frequency of CTNNB1 was significantly higher in HCC (P < 0.01). The rate of CTNNB1 mutation was significantly less frequent in Hepatitis B virus-related HCC than in other etiologies (P < 0.01). Dual-luciferase reporter system and TOP/FOP reporter assays confirmed that TP53 GOF mutants were able to enhance the transcriptional ability of Wnt signaling. An exclusive relationship between the status of TP53 and CTNNB1 mutations was observed. However, according to the COSMIC database, TP53 GOF mutation is rare in HCC, which indicates that TP53 GOF mutation is not a reason for the aberrant activation of Wnt signaling in HCC. APC and AXIN1 were mutated in HCC. By using methylation sensitive restriction enzyme-quantitative PCR, hypermethylation of APC was detected in HCC with different risk factors, whereas SFRP1 and SFRP5 were not hypermethylated in any of the HCC etiologies, which indicates that the mutation of APC and AXIN1, together with the methylation of APC could take part in the overactivation of Wnt signaling. Nested-reverse transcription PCR failed to detect the integration of HBx before the LINE1 element, or the existence of an HBx-LINE1 chimeric transcript, suggesting that integration could not play a role in the aberrant activation of Wnt signaling in HCC. CONCLUSION: In HCC, genetic/epigenetic aberration of CTNNB1 and its protein degradation regulators are the major cause of Wnt signaling overactivation.

4 March 2020 in BMJ Open Diabetes Research & Care
Verified
Journal Article
Open access
PDF file
KZKenneth I Zheng
Kenneth I Zheng
WLWen-Yue Liu
Wen-Yue Liu
XPXiao-Yan Pan
Xiao-Yan Pan
HMHong-Lei Ma
Hong-Lei Ma
PZPei-Wu Zhu
Pei-Wu Zhu
MZMing-Hua Zheng
Ming-Hua Zheng
Background and aim Imaging-confirmed non-alcoholic fatty liver disease (NAFLD) with normal alanine aminotransferase (nALT) levels is infrequently the subject for further evaluation. Early diagnosis of non-alcoholic steatohepatitis (NASH) is needed to prevent disease progression. Thus, we tested the clinical utility of serum Golgi protein 73 (GP73) levels and developed a new non-invasive score to diagnose NASH in patients with biopsy-confirmed NAFLD and persistent nALT levels. Methods Serum GP73 and cytokeratin-18 M30 fragments (CK18-M30) levels were measured in 345 patients with biopsy-proven NAFLD. We developed a new score, named G-NASH model (by incorporating serum GP73), and combined it with serum CK18-M30 measurement in a sequential non-invasive approach to accurately identify NASH among patients with NAFLD and persistent nALT levels. Results 105 (30.4%) patients had persistent nALT, 53 of whom had histologically confirmed NASH. Both serum GP73 and CK18-M30 levels alone had poor diagnostic accuracy in identifying NASH (55.2% and 51.6%, respectively) in these patients. Conversely, G-NASH model performed better than other established non-invasive scoring systems, and by using our proposed sequential non-invasive approach 82.9% of patients with NASH were correctly identified. Conclusions NASH is highly prevalent in patients with NAFLD with persistent nALT levels. The G-NASH model accurately identifies NASH in this patient group.

1 December 2018 in Experimental Cell Research
Verified
Journal Article
Closed access
ZGZhengyang Guo
Zhengyang Guo
JJJunqiao Jia
Junqiao Jia
MYMingjie Yao
Mingjie Yao
JKJingting Kang
Jingting Kang
YWYongfeng Wang
Yongfeng Wang
FLFeng-min Lu
Feng-min Lu

1 July 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
XLXinjie Li
Xinjie Li
YYYue Yin
Yue Yin
LPLing Pang
Ling Pang
SXShuyun Xu
Shuyun Xu
FLFeng-min Lu
Feng-min Lu
TSTao Shen
Tao Shen
A large number of COVID-19 patients are in recovery and millions of people are vaccinated COVID-19 vaccines globally daily. This calls for a rapid screening strategy of SARS-CoV-2 protective antibodies generated in rehabilitators and vaccinated populations. Serum samples collected over a follow-up period of 6 months from 306 COVID-19 cases discharged from Wuhan Tongji Hospital were analyzed. Anti-S Abs were detected by colloidal gold immunochromatographic assay (GICA) and neutralizing antibodies (nAbs) were detected by chemiluminescent microparticle immunoassay (CMIA). Most COVID-19 survivors tested positive for anti-S Abs (83.7%) and nAbs (98.0%) 6 months after being discharged from the hospital, and the levels of anti-S Abs in the blood were highly positively correlated with nAbs (r = 0.652, P < 0.0001). The positivity rate of nAbs for patients with anti-S Abs positive was 100%. There is a good agreement between anti-S Abs detected by GICA and nAbs detected by CMIA. It indicates that anti-S Abs detected by GICA may be used as a cheaper screening strategy for detectable SARS-CoV-2 nAbs in COVID-19 convalescent individuals.